EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Connective tissue disease‐associated interstitial lung disease: an approach to treatment amidst an expanding evidence base

Michael Hong, Elizabeth Veitch, Sandhya Limaye iD

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Michael Hong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Concord Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Connective Tissue Diseases, Evidence-Based Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Connective tissue disease‐associated interstitial lung disease (CTD‐ILD) comprises a heterogenous group of conditions characterised by immune‐mediated fibro‐inflammatory pulmonary injury. Although the disease course is variable, CTD‐ILD can progress to respiratory failure and thus has a profound impact on morbidity and mortality. Systemic sclerosis (SSc), rheumatoid arthritis, idiopathic inflammatory myositis, Sjogren disease systemic lupus erythematosus and mixed connective tissue disease can all manifest or present with ILD. Histological injury in CTD‐ILD is diverse and pharmacological management, when indicated, is typically centred around corticosteroids and various immunosuppressive or anti‐fibrotic agents. Until recently, treatment decisions have been extrapolated from the evidence base available for SSc‐related ILD. Many recent trials and prospective studies have evaluated treatment options in a range of CTD‐ILD, thus guiding therapeutic intervention. Amidst an expanding evidence base, this comprehensive review describes new management strategies in CTD‐ILD with a focus on evidence from clinical trials. Supportive care and minimising treatment‐associated adverse effects remains paramount in this population with complex respiratory pathology and frequent co‐morbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialConnective Tissue DiseasesEvidence-Based MedicineHumansImmunosuppressive Agents

Stichwörter der Autor:innen

connective tissue disorderimmunosuppressioninflammatory myositisinterstitial lung diseaserheumatoid arthritissystemic sclerosis

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Immunology, Concord Hospital, Sydney, New South Wales, Australia.
  • University of Sydney Concord Clinical School, Sydney, New South Wales, Australia.
  • Department of Respiratory Medicine, Concord Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Sandhya Limaye

Zitieren

APA

Hong, M., Veitch, E., & Limaye, S. (2025). Connective tissue disease‐associated interstitial lung disease: an approach to treatment amidst an expanding evidence base. Internal Medicine Journal. https://doi.org/10.1111/imj.70026

Vancouver

Hong M, Veitch E, Limaye S. Connective tissue disease‐associated interstitial lung disease: an approach to treatment amidst an expanding evidence base. Internal Medicine Journal. 2025. doi:10.1111/imj.70026

BibTeX
@article{Hong2025,
  author = {Hong, Michael and Veitch, Elizabeth and Limaye, Sandhya},
  title = {Connective tissue disease‐associated interstitial lung disease: an approach to treatment amidst an expanding evidence base},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70026}
}
Kostenlos starten →